Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

• DOI: 10.3389/fpubh.2022.1008521
• Publication Date: 2022-09-21T05:21:46Z
• Authors: Hafez Al-Momani; Khawla Aldajah; Ebtisam Alda'ajah; Yousef ALjafar; Zainab Abushawer
• Keywords: Disease Control

Background There is a need to establish the effectiveness of coronavirus disease 2019 (COVID-19) vaccines in reducing COVID-19-related hopitalization patients Jordan. As vaccination program accelerates, it important determine whether vaccines' (VE) has successfully reduced number acute cases admitted hospital. Methods To efficacy Pfizer-BioNTech and Sinopharm COVID-19 among Jordanian Prince Hamza hospital, single center case-control study was performed. The analyzed hospitalization rates vaccinated ( n = 536) unvaccinated 585) individuals across 2-month period from February 6 April 6, 2022. were who tested positive for SARS-CoV-2 (“case-patients”), whilst control group hospital did not test (“control-patients”). Results This found that 1,121 total participants (561 560 control), overall vaccine 84% (95% Cl 79–88%). VE higher females (88%, 95% 84–93%) than males (77%, 67–84%) p < 0.001), highest those between ages 18 28-years-old (95%, CI 86–98%). For with pre-existing conditions, including chronic heart disease, lung diabetes, compared no comorbidities, though difference statistically significant. Finally, comparing all participants, received Pfizer (VE 92%, 88–94%) (OR 0.08, 0.06–0.12) 67%, 52–78%) 0.33, 0.22–0.48); 0.011). Conclusion Overall, be effective limiting hospitalizations adult's patient's cohort 2022, especially comorbidities.